Fabian Gerlinghaus, Cellares CEO
Updated: Cellares to produce Cabaletta’s autoimmune CAR-T candidateÂ
Cellares announced a new proof-of-concept partnership with Cabaletta Bio to manufacture the biotech’s autoimmune CAR-T cell therapy.
The goal of the program is to test …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.